Syndax Pharmaceuticals Inc — Insider Transactions
Form 4 filings by directors, officers, and 10%+ shareholders
SEC rules require corporate insiders — including directors, executive officers, and any shareholder owning more than 10% of a company's shares — to report changes in their ownership within two business days of a transaction. These disclosures are filed as Form 4. Open-market purchases (code P) are generally considered the most meaningful signal, as insiders are spending their own money.
| Insider | Title | Type | Shares | Price | Value | Owns After | Date |
|---|---|---|---|---|---|---|---|
| Goldan Keith A. | Chief Financial Officer | Gift | 1,224 | — | — | 92,452 | Dec 1, 2025 |
| Metzger Michael A | Chief Executive Officer | Option Exercise | 157,307 | $10.90 | $1,714,646 | 455,968 | Sep 8, 2025 |
| Podlesak Dennis | — | Option Exercise | 19,200 | $7.20 | $138,240 | 210,963 | Aug 18, 2025 |
| Goldan Keith A. | Chief Financial Officer | Other | 1,226 | $8.43 | $10,335 | 93,676 | Jul 31, 2025 |
| Goldan Keith A. | Chief Financial Officer | Sale | 1,296 | $9.29 | $12,040 | 92,450 | Jul 16, 2025 |
| Metzger Michael A | Chief Executive Officer | Sale | 7,534 | $9.29 | $69,991 | 298,661 | Jul 16, 2025 |
| Goldan Keith A. | Chief Financial Officer | Purchase | 3,000 | — | — | 93,746 | May 19, 2025 |
| Huber Martin H. Jr. | — | Purchase | 5,000 | $8.99 | $44,950 | 79,000 | May 19, 2025 |
| Katkin Keith | — | Purchase | 10,000 | $9.11 | $91,100 | 100,000 | May 19, 2025 |
| Botwood Nicholas A.J. | Head of R&D, CMO | Purchase | 11,765 | $9.00 | $105,885 | 35,165 | May 16, 2025 |
| Metzger Michael A | Chief Executive Officer | Option Exercise | 6,074 | $7.20 | $43,733 | 306,195 | Mar 14, 2025 |
| Metzger Michael A | Chief Executive Officer | Option Exercise | 7,814 | $7.20 | $56,261 | 307,935 | Mar 4, 2025 |
| Goldan Keith A. | Chief Financial Officer | Sale | 3,777 | $15.50 | $58,544 | 90,746 | Feb 10, 2025 |
| Metzger Michael A | Chief Executive Officer | Sale | 13,288 | $15.50 | $205,964 | 300,121 | Feb 10, 2025 |
| Gallagher Neil | President, Head of R&D | Sale | 4,618 | $15.50 | $71,579 | 85,095 | Feb 10, 2025 |
| Gallagher Neil | President, Head of R&D | Award / Grant | 18,500 | — | — | 66,313 | Feb 5, 2025 |
| Goldan Keith A. | Chief Financial Officer | Award / Grant | 23,400 | — | — | 94,523 | Feb 5, 2025 |
| Metzger Michael A | Chief Executive Officer | Award / Grant | 60,500 | — | — | 224,409 | Feb 5, 2025 |
| Podlesak Dennis | — | Award / Grant | 50,000 | — | — | 191,763 | Feb 5, 2025 |
| Rizo Aleksandra | — | Award / Grant | 25,000 | — | — | 25,000 | Feb 5, 2025 |
| Meury William | — | Award / Grant | 25,000 | — | — | 90,000 | Feb 5, 2025 |
| Katkin Keith | — | Award / Grant | 25,000 | — | — | 90,000 | Feb 5, 2025 |
| Jarrett Jennifer | — | Award / Grant | 25,000 | — | — | 90,000 | Feb 5, 2025 |
| Huber Martin H. Jr. | — | Award / Grant | 25,000 | — | — | 74,000 | Feb 5, 2025 |
| Legault Pierre | — | Award / Grant | 25,000 | — | — | 90,000 | Feb 5, 2025 |
| Goldan Keith A. | Chief Financial Officer | Purchase | 1,250 | $20.03 | $25,038 | 52,623 | Jun 14, 2024 |
| Metzger Michael A | Chief Executive Officer | Award / Grant | 39,000 | — | — | 163,909 | Feb 7, 2024 |
| Goldan Keith A. | Chief Financial Officer | Award / Grant | 35,000 | — | — | 39,673 | Feb 7, 2024 |
| Gallagher Neil | President, Head of R&D | Award / Grant | 13,125 | — | — | 47,813 | Feb 7, 2024 |
| Huber Martin H. Jr. | — | Award / Grant | 17,000 | — | — | 49,000 | Feb 7, 2024 |
| Jarrett Jennifer | — | Award / Grant | 17,000 | — | — | 65,000 | Feb 7, 2024 |
| Katkin Keith | — | Award / Grant | 17,000 | — | — | 65,000 | Feb 7, 2024 |
| Meury William | — | Award / Grant | 17,000 | — | — | 65,000 | Feb 7, 2024 |
| Morrison Briggs | — | Award / Grant | 17,000 | — | — | 34,836 | Feb 7, 2024 |
| Podlesak Dennis | — | Award / Grant | 34,000 | — | — | 141,763 | Feb 7, 2024 |
| Legault Pierre | — | Award / Grant | 17,000 | — | — | 65,000 | Feb 7, 2024 |
| Morrison Briggs | — | Option Exercise | 52,855 | $8.77 | $463,538 | 70,691 | Aug 9, 2023 |
| Meury William | — | Sale | 35,000 | $20.46 | $716,100 | 48,000 | Aug 2, 2023 |
| Morrison Briggs | — | Option Exercise | 52,855 | $8.77 | $463,538 | 70,691 | Jul 10, 2023 |
| Goldan Keith A. | Chief Financial Officer | Sale | 577 | $22.31 | $12,873 | 2,628 | Jun 13, 2023 |
| Morrison Briggs | — | Option Exercise | 28,273 | $8.77 | $247,954 | 70,691 | Jun 9, 2023 |
| Morrison Briggs | — | Sale | 52,855 | $21.41 | $1,131,626 | 17,836 | May 9, 2023 |
| Morrison Briggs | — | Sale | 52,855 | $19.53 | $1,032,258 | 17,836 | Apr 10, 2023 |
| Morrison Briggs | President, Head of R&D | Option Exercise | 52,854 | $6.38 | $337,209 | 70,690 | Mar 13, 2023 |
| Ordentlich Peter | Chief Scientific Officer | Sale | 17,428 | $25.84 | $450,340 | — | Feb 15, 2023 |
| Metzger Michael A | Chief Executive Officer | Option Exercise | 5,959 | $6.38 | $38,018 | 23,618 | Feb 6, 2023 |
| Morrison Briggs | President, Head of R&D | Sale | 52,854 | $26.83 | $1,418,073 | 17,836 | Feb 6, 2023 |
| Podlesak Dennis | — | Award / Grant | 32,000 | — | — | 107,763 | Feb 2, 2023 |
| Huber Martin H. Jr. | — | Award / Grant | 16,000 | — | — | 32,000 | Feb 2, 2023 |
| Meury William | — | Award / Grant | 16,000 | — | — | 48,000 | Feb 2, 2023 |